Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering

Area of Science:

• Gastroenterology and Immunology
• Microbiome Research
• Biotechnology

Background:

• Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), involves chronic gastrointestinal inflammation with immune dysregulation and altered gut microbiota.
• Current treatments, including biologics, offer improved remission but patients still face long-term complications.
• The gut microbiome is increasingly recognized for its role in human health, presenting opportunities for novel therapeutic strategies.

Purpose of the Study:

• To review current pharmacological and non-pharmacological treatments for IBD.
• To highlight the potential of engineered probiotics in managing IBD.
• To discuss the development of personalized probiotic therapies based on individual gut microbiome variations.

Main Methods:

• Review of existing literature on IBD treatments.
• Focus on probiotic engineering techniques and their application.
• Analysis of anti-inflammatory cytokine production by engineered probiotics.

Main Results:

• Engineered probiotics can be designed to produce therapeutic biologics, specifically anti-inflammatory cytokines.
• These engineered probiotics are being utilized to treat intestinal inflammation in IBD patients.
• The diversity of the gut microbiome necessitates personalized approaches to probiotic therapy.

Conclusions:

• Engineered probiotics represent a significant advancement in IBD treatment, offering targeted anti-inflammatory action.
• Personalized probiotic strategies hold promise for addressing the complexities of IBD in diverse populations.
• Further development in biological engineering is crucial for realizing the full potential of probiotic-based therapies for chronic inflammatory conditions.